全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Delayed Diagnosis of Nasal Natural Killer/T-Cell Lymphoma

DOI: 10.1155/2013/918132

Full-Text   Cite this paper   Add to My Lib

Abstract:

Midline destructive lesions of the face have multiple possible etiologies. The majority of these cases are found to be due to an extranodal lymphoma of natural killer/T-cell-type non-Hodgkins lymphoma (NKTL). Unfortunately, diagnosis is often delayed. With variable presenting complaints, including nonspecific issues like chronic rhinosinusitis or nasal congestion, initial treatments are aimed at these presumed diagnoses. Only as the lesion progresses do overt signs of destruction occur. As with our patient, who was initially treated for presumed infection and abscess, final diagnosis often does not occur until several months, and several antibiotic courses, from initial presentation. As such, it is important for this rare entity to remain in the clinician’s differential diagnosis for nasal lesion. 1. Introduction Midline destructive lesions (MDLs) of the face were first reported in the late nineteenth century. These later became known as lethal midline granulomas. Other monikers such as idiopathic midline granuloma, idiopathic midline destructive disease, midline nonhealing granuloma, polymorphic reticulosis, and Stewart syndrome have also been used to describe this destructive process of the nose. Regardless of the name used, an ulcerative process, characterized by loss of both epithelium and cartilage with associated nasal crusting, occurs. Ultimately, there is loss of nasal structure and support, leading to nasal deformity [1]. After thorough workup, the majority of these cases—as in the case presented in this paper—are found to be due to an extranodal lymphoma of natural killer/T-cell lymphoma (NKTL). Though rare, NKTL is the most common form of sinonasal lymphoma and, thus, should be included in the differential for destructive lesions of the nasal cavity or midline face. There is a strong association with Epstein-Barr virus (EBV) and other epidemiologic risk factors including Asian or Central and South American descent, male gender, and age 50 to 55 [2–4]. In the United States and other Western countries NKTL accounts for less than 2% of all non-Hodgkins lymphoma. Presentation is variable but most commonly includes nonspecific complaints of chronic rhinosinusitis, with initial treatments aimed at this presumed diagnosis. As the lesion progresses, patients may have additional complaints such as disruption of normal nasal airflow leading to epistaxis and nasal dyspnea, palatal destruction, associated orbital edema and erythema, and facial pain. Intranasal examination may reveal mild to significant crusting with extensive ulceration and destruction

References

[1]  Y. S. Paik, B. D. Liess, T. D. Scheidt, E. A. Ingram, and R. P. Zitsch III, “Extranodal nasal-type natural killer/T-cell lymphoma masquerading as recalcitrant sinusitis,” Head and Neck, vol. 32, no. 2, pp. 268–273, 2010.
[2]  A. Sharma, M. Dandekar, S. Deshmukh, and J. Dabholkar, “Nasal extranodal natural killer T cell lymphoma: an atypical presentation,” Journal of Laryngology and Otology, vol. 125, no. 11, pp. 1181–1184, 2011.
[3]  N. P. Parker, A. N. Pearlman, D. B. Conley, R. C. Kern, and R. K. Chandra, “The dilemma of midline destructive lesions: a case series and diagnostic review,” American Journal of Otolaryngology, vol. 31, no. 2, pp. 104–109, 2010.
[4]  J. Lee, S.-G. Cho, S.-M. Chung, et al., “Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL),” Annals of Hematology, vol. 92, no. 3, pp. 333–343, 2013.
[5]  J. H. Turner, M. Loyo, and S. Y. Lin, “Aggressive sinonasal natural killer/T-cell lymphoma with hemophagocytic lymphohistiocytosis,” American Journal of Otolaryngology, vol. 33, no. 1, pp. 188–191, 2012.
[6]  G. C. Ooi, C. S. Chim, R. Liang, K. W. T. Tsang, and Y. L. Kwong, “Original report. Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity,” American Journal of Roentgenology, vol. 174, no. 4, pp. 1141–1145, 2000.
[7]  M. Kondo, M. Horiuchi, and H. Shiga, “Computed tomography of malignant tumors of the nasal cavity and paranasal sinuses,” Cancer, vol. 50, no. 2, pp. 226–231, 1982.
[8]  C.-Y. Lin and P.-W. Cheng, “Nasal natural killer/T-cell lymphoma,” Otolaryngology, vol. 143, no. 3, pp. 461–462, 2010.
[9]  Y. Charli-Joseph, M. Saeb-Lima, A. Hernández-Salazar, and J. Domínguez-Cherit, “Nasal-type extranodal natural killer/T-cell lymphoma presenting as genital ulcers,” Journal of the American Academy of Dermatology, vol. 67, no. 4, pp. e157–e159, 2012.
[10]  L. Wang, Z.-H. Wang, X.-Q. Chen, et al., “First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma,” Cancer, vol. 119, no. 2, pp. 348–355, 2013.
[11]  R. Liang, “Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type,” British Journal of Haematology, vol. 147, no. 1, pp. 13–21, 2009.
[12]  M. Yamaguchi, K. Tobinai, M. Oguchi, et al., “Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211,” Journal of Clinical Oncology, vol. 30, no. 32, pp. 4044–4046, 2012.
[13]  H. J. Kim, S. M. Bang, J. Lee et al., “High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: A retrospective comparison with non-transplantation cases,” Bone Marrow Transplantation, vol. 37, no. 9, pp. 819–824, 2006.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133